Table 4 Prognostic value of NUCB2 protein expression for the overall survival in univariate and multivariate analyses by Cox regression
From: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer
Covariant | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Exp (B) | 95% CI | P value | Exp (B) | 95% CI | P value | |
NUCB2 protein expression (high/low) | 2.978 | 1.516-6.181 | <0.001 | 3.152 | 1.317-6.214 | <0.001 |
Gleason score (> 7/7/< 7) | 2.526 | 1.788-3.568 | <0.001 | 2.014 | 1.217-2.869 | <0.001 |
PSA (>10/4-10/< 4) | 2.034 | 1.338-23.092 | 0.001 | 1.989 | 1.292-3.053 | <0.001 |
Age (≥65/< 65) | 1.282 | 0.917-1.792 | 0.146 | |||
Angiolymphatic invasion (presence/absence) | 1.373 | 0.813-2.319 | 0.235 | |||
Surgical margin status (presence/absence) | 1.101 | 0.703-1.724 | 0.674 | |||
PCa Stage (T2, T3/T1) | 4.131 | 2.888-5.911 | <0.001 | 3.671 | 2.656-5.715 | <0.001 |
Lymph node metastasis (presence/absence) | 1.044 | 0.746-1.462 | 0.800 | |||
Seminal vesicle invasion (presence/absence) | 1.358 | 0.956-1.928 | 0.087 | |||